US-Listed In Vitro & In Vivo Diagnostic Substances — Revenue Percentiles
Population: 17 US-listed companies (SIC 2835), most recent complete fiscal year per filer; fiscal year ends 2025-02-28 to 2026-05-31.
| 10th percentile | $932.9k |
|---|
| 25th percentile | $4.1M |
|---|
| Median | $9.2M |
|---|
| 75th percentile | $824.5M |
|---|
| 90th percentile | $2.0B |
|---|
| Mean | $614.3M |
|---|
| Minimum | $0 |
|---|
| Maximum | $4.3B |
|---|
Methodology & sources
Revenue as filed in the most recent complete fiscal year per company (period > 300 days, fiscal year end within the last 18 months); percentiles computed in the database via percentile_cont, never by a model.
Source: SEC EDGAR filings (public domain). Data: FACTANKER registry, as of 2026-05-31.
Scope: {"source": "SEC EDGAR: api.mv_sic x api.v_company_financials (as-filed)", "selection": "je Firma das jüngste volle Geschäftsjahr (>300 Tage, Ende in den letzten 18 Monaten); Umsatzband filtert über de
Evidence samples
Query this live via API/MCP (template peer_percentiles); terms: /nutzung. Cite as: FACTANKER, https://factanker.com/industries/sic-2835/revenue